Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness becomes Alere

This article was originally published in The Gray Sheet

Executive Summary

Inverness Medical Innovations plans to change its name to Alere as part of a strategy to leverage its combined offerings and maximize visibility and growth, the firm announces May 18. The diagnostics and health management services firm currently uses the Alere name (which means "to nurture" in Latin) for its health management services. "Therefore, the name already benefits from recognition within the healthcare community," the firm says. Inverness acquired health management services firm Alere in 2007 and will seek shareholder approval for the name change at its July 14 annual meeting; the company's stock symbol would change from "IMA" to "ALR" (1"The Gray Sheet" Oct. 29, 2007)

You may also be interested in...



Inverness acquires Alere

Inverness Medical Innovations continues its acquisition spree with the $302 million purchase of Alere, a provider of health and care-management services for patients with heart failure and other chronic illnesses, in agreement announced Oct. 24. The purchase complements Inverness's cardiac management and diagnostic technologies, and is consistent with the firm's overall acquisition strategy, according to CEO Ron Zwanziger (1"The Gray Sheet" Sept. 3, 2007, p. 9). The transaction, which includes $125 million in cash and $177 million in Inverness common stock, is expected to close at the end of 2007. Alere is expected to have 2007 revenues of $77 million

Biogen’s Recipe For Success In Knowledge Management

Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.

Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

Topics

UsernamePublicRestriction

Register

MT028916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel